Kaufman Bros. Starts Hologic (HOLX) at Buy; Positive Leverage to 3D Mammography, a New Technology Cycle Offsetting Weak Capex Markets

Kaufman Bros. initiates coverage on Hologic (NASDAQ: HOLX) with a Buy. PT $19.00.

Kaufman analyst says, "We believe the company is levered to a new technology cycle with the February 2011 FDA clearance of its 3D Tomosynthesis system, with early adopters eager to prove out the technology and drive clinical data, offsetting weak capex market trends. In the U.S., where Hologic holds around 60% share of 2D mammography systems, early adopters comprise approximately 500-700 of the currently installed ~5,200 2D systems. Our high-single-to-low-teens breast health revenue growth outlook in F11E-F13E assumes lift from around 600 early adopters."

For more ratings news on Hologic click here and for the rating history of Hologic click here.

Shares of Hologic closed at $15.71 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Leerink Starts Ligand Pharma (LGND) at Outperform
• Lake Street Starts RF Industries Ltd. (RFIL) at Buy